You are here

FDA Approves Qtern for Adults With Type-2 Diabetes

Once-daily treatment combines SGLT-2 inhibitor and DPP-4 inhibitor

The FDA has approved once-daily Qtern (10 mg dapagliflozin and 5 mg saxagliptin, AstraZeneca) as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes who have inadequate control with dapagliflozin 10 mg (Farxiga, AstraZeneca) or who are already treated with dapagliflozin and saxagliptin (Onglyza, AstraZeneca).

Qtern combines two antihyperglycemic agents with complementary mechanisms of action in a once-daily tablet: dapagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, and saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor.

SGLT-2 inhibitors help patients achieve improved glycemic control by reducing the reabsorption of glucose from the blood and enabling its removal via the urine. SGLT-2 inhibitors, including dapagliflozin, have demonstrated reductions in hemoglobin A1c (HbA1c) and have also reduced weight and blood pressure. DPP-4 inhibitors reduce blood glucose, as measured by HbA1c.

The FDA approved Qtern based on data from a 24-week, phase 3, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of saxagliptin added to dapagliflozin in 315 adults with type-2 diabetes who experienced inadequate glycemic control (HbA1c ranging from 7.0% to 10.5%) with metformin (1,500 mg/day or more). The safety of the combined use of dapagliflozin and saxagliptin was evaluated in a pooled safety analysis of three phase 3, placebo-controlled clinical trials, in which 492 patients were treated with Qtern for up to 52 weeks.

Source: AstraZeneca; February 28, 2017.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs